medigraphic.com
ISSN 1729-519X (Print)

2019, Number 5

<< Back Next >>

Revista Habanera de Ciencias Médicas 2019; 18 (5)

Fundus flavimaculatus. Case presentation

Álvarez LD, Baglán PA, Herreras CO

Language: Spanish
References: 19
Page: 778-785
PDF size: 733.20 Kb.


ABSTRACT

Introduction: Stargardt´s Disease or fundus flavimaculatus is the most frequent juvenile macular dystrophy that is responsible for 7 % of macular dystrophies. They can be difficult to address because of several reasons. The differential diagnosis is sometimes difficult to make and some of these diseases can cause legal blindness at a relatively young age.
Objective: To describe the diagnostic process of an unusual entity with an infrequent form of presentation.
Case presentation: We present a case of a 21- year-old white female patient with the diagnosis of Stargardt´s Disease with fundus flavimaculatus. The diagnosis was made taking into account personal pathological antecedents, the physical examination by direct and indirect ophthalmoscopy, assessment of visual acuity with and without correction, color vision test, fluorescein angiography, optical coherence tomography (OCT), and electroretinogram. Research on the topic was carried out because of the unusual appearance of these two variants of the same disease in the first decade of life.
Conclusions: The majority of retinal dystrophies are similar from the clinical point of view; however, their evolution and prognosis can be different.


REFERENCES

  1. Medina López JP, Parada Vázquez RH, Rodríguez Gómez JA, Castillo Velázquez J. Enfermedad de Stargardt: presentación clínica de cuatro casos familiares. Oftalmol Clin Exp. 2016; 9(3):108-15.

  2. Wright LS, Phillips MJ, Pinilla I, Hei D, Gamm DM. Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res. 2014; 123:161-72.

  3. Ritter M, Zotter S, Schmidt WM, Bittner RE, Deak GG, Pircher M, et al. Characterization of Stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging. Invest Ophthalmol Vis Sci [Internet]. 2013;54(9):23. [Citado 20/09/2019]. Disponible en: https://iovs.arvojournals.org/article.aspx?articleid=2 128276

  4. Cai CX, Light JG, Handa JT. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease [Internet]. 2018;186:20. [Citado 20/09/2019]. Disponible en: https://www.clinicalkey.es/#!/content/playContent/ 1-s2.0- S0002939417304713?returnurl=https:%2F%2Flinking hub.elsevier.com%2Fretrieve%2Fpii%2FS000293941 7304713%3Fshowall%3Dtrue&referrer=https:%2F%2 Fwww.researchgate.net%2F

  5. Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt’s disease. Ophthalmology [Internet]. 2012;119(6):[aprox. 22p.]. [Citado 20/09/2019]. Disponible en: https://www.clinicalkey.es/#!/content/playContent/ 1-s2.0- S0161642012000097?returnurl=https:%2F%2Flinking hub.elsevier.com%2Fretrieve%2Fpii%2FS016164201 2000097%3Fshowall%3Dtrue&referrer=https:%2F%2 Fwww.ncbi.nlm.nih.gov%2F

  6. McBain VA, Townend J, Lois N. Progression of retinal pigment epithelial atrophy in Stargardt disease. Am J Ophthalmol [Internet]. 2012;154(1):[aprox. 33p.]. [Citado 20/09/2019]. Disponible en: https://www.clinicalkey.es/#!/content/playContent/ 1-s2.0- S0002939412000700?returnurl=https:%2F%2Flinking hub.elsevier.com%2Fretrieve%2Fpii%2FS000293941 2000700%3Fshowall%3Dtrue&referrer=https:%2F%2 Fwww.researchgate.net%2F

  7. Wright LS, Phillips MJ, Pinilla I, Hei D, Gamm DM. Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res. 2014; 123: 161-72.

  8. Kanski JJ, Bowling B. Kanski Oftalmología clínica. 7ma. ed. Madrid: Elsevier; 2012.

  9. Sangermano R, Khan M, Cornelis SS, Richelle V, Albert S, Garanto A, et al. ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in Stargardt disease. Genome Res [Internet]. 2018;28(1):25. [Citado 20/09/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC574 9174/

  10. Fujinami K, Lois N, Davidson AE, Mackay DS, Hogg CR, Stone EM,et al. A longitudinal study of Stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. Am J Ophthalmol [Internet]. 2013 Jun;155(6):23. [Citado 20/09/2019]. Disponible en: https://www.clinicalkey.es/#!/content/playContent/ 1-s2.0- S0002939413000743?returnurl=https:%2F%2Flinking hub.elsevier.com%2Fretrieve%2Fpii%2FS000293941 3000743%3Fshowall%3Dtrue&referrer=https:%2F%2 Fwww.ncbi.nlm.nih.gov%2F

  11. Testa F, Rossi S, Sodi A,Passerini I,Di Lorio V, Della Corte M,et al. Correlation between photoreceptor layer integrity and visual function in patients with Stargardt disease: implications for gene therapy. Invest Ophthalmol Vis Sci 2012; 53(8):4409-15.

  12. Gérard X, Perrault I, Munnich A, Kaplan J, Rozet JM. Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells. Mol Ther Nucleic Acids [Internet]. 2015 Sep;4(9):22. [Citado 20/09/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC487 7449/

  13. Murray SF, Jazayeri A, Matthes MT, Yasumura D, Yang H, Peralta R, et al. Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration. Invest Ophthalmol Vis Sci [Internet]. 2015;56(11):25. [Citado 20/09/2019]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC510 4522/

  14. Lambertus S, Bax NM, Groenewoud JMM, et al. Asymmetric inter-eye progression in Stargardt disease. Invest Ophthalmol Vis Sci. 2016; 57(15):6824- 30.

  15. Cai CX, Locke KG, Ramachandran R, Birch DG, Hood DC. A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and xlinked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2014;55(11):7417-22.

  16. Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with x-linked retinitis pigmentosa. JAMA Ophthalmol. 2013; 131(9):1143- 50.

  17. Hariri AH, Velaga SB, Girach A, et al. Measurement and reproducibility of preserved ellipsoid zone area and preserved RPE area in a cohort of eyes with choroideremia. Am J Ophthalmol. 2017; 179:110-17.

  18. Strauss RW, Ho A, Muńoz B, Cideciyan AV, Sahel JA, Sunness JS, et al. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (Prog- Star) studies: design and baseline characteristics: ProgStar Report No. 1. Ophthalmology. 2016; 123(4):817-28.

  19. Cideciyan AV, Alemán TS, Swider M, Schwartz SB, Steinberg JD, Brucker AJ. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet. 2004; 13(5):525-34.




2020     |     www.medigraphic.com